Sikai Ling

606 total citations · 3 hit papers
5 papers, 345 citations indexed

About

Sikai Ling is a scholar working on Molecular Biology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Sikai Ling has authored 5 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 2 papers in Epidemiology and 1 paper in Infectious Diseases. Recurrent topics in Sikai Ling's work include CRISPR and Genetic Engineering (3 papers), Retinal Development and Disorders (2 papers) and Herpesvirus Infections and Treatments (2 papers). Sikai Ling is often cited by papers focused on CRISPR and Genetic Engineering (3 papers), Retinal Development and Disorders (2 papers) and Herpesvirus Infections and Treatments (2 papers). Sikai Ling collaborates with scholars based in China, Denmark and Sweden. Sikai Ling's co-authors include Yujia Cai, Jiaxu Hong, Di Yin, Søren R. Paludan, Yao Dai, Dawei Wang, Xujiao Zhou, Hao Jiang, Xiaoqing Qian and Xiaodong Sun and has published in prestigious journals such as Nature Biotechnology, Nature Nanotechnology and Cell stem cell.

In The Last Decade

Sikai Ling

5 papers receiving 341 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice

2021 122 citations Di Yin, Sikai Ling et al. Nature Biotechnology profile →
Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial

2024 41 citations Sikai Ling, Dawei Wang et al. Cell stem cell profile →
Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy

2025 18 citations Sikai Ling, Xue Zhang et al. Nature Nanotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sikai Ling China	5	268	85	54	38	32	5	345
Kirsten Bucher Germany	9	208 0.8×	74 0.9×	30 0.6×	74 1.9×	28 0.9×	16	347
Sivaprakash Ramalingam India	12	414 1.5×	100 1.2×	21 0.4×	8 0.2×	21 0.7×	38	498
Axel Rossi Germany	8	246 0.9×	204 2.4×	20 0.4×	19 0.5×	7 0.2×	13	307
Lester Suárez-Amarán Spain	6	158 0.6×	132 1.6×	85 1.6×	4 0.1×	31 1.0×	6	315
Wenqin Ma United States	10	359 1.3×	386 4.5×	50 0.9×	10 0.3×	16 0.5×	13	466
Margot L. Goodkin United States	10	96 0.4×	36 0.4×	122 2.3×	138 3.6×	30 0.9×	21	322
You Kyeong Jeong South Korea	8	580 2.2×	136 1.6×	47 0.9×	7 0.2×	34 1.1×	11	599
Debojyoti Chakraborty India	15	474 1.8×	57 0.7×	16 0.3×	6 0.2×	26 0.8×	32	525
Karen Lee United States	10	233 0.9×	13 0.2×	21 0.4×	48 1.3×	8 0.3×	20	327
Sarah Nehls United States	6	153 0.6×	20 0.2×	26 0.5×	44 1.2×	91 2.8×	16	354

Countries citing papers authored by Sikai Ling

Since Specialization

Citations

This map shows the geographic impact of Sikai Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sikai Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sikai Ling more than expected).

Fields of papers citing papers by Sikai Ling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sikai Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sikai Ling. The network helps show where Sikai Ling may publish in the future.

Co-authorship network of co-authors of Sikai Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Sikai Ling. A scholar is included among the top collaborators of Sikai Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sikai Ling. Sikai Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Ling, Sikai, Xue Zhang, Yao Dai, et al.. (2025). Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy. Nature Nanotechnology. 20(4). 543–553. 18 indexed citations breakdown →

2.

Ling, Sikai, Dawei Wang, Xiaoyuan Wang, et al.. (2024). Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial. Cell stem cell. 31(7). 961–973.e8. 41 indexed citations breakdown →

3.

Wei, Anji, Di Yin, Sikai Ling, et al.. (2023). In vivo CRISPR gene editing in patients with herpetic stromal keratitis. Molecular Therapy. 31(11). 3163–3175. 29 indexed citations

4.

Yin, Di, Sikai Ling, Dawei Wang, et al.. (2021). Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice. Nature Biotechnology. 39(5). 567–577. 122 indexed citations breakdown →

5.

Ling, Sikai, Shiqi Yang, Xinde Hu, et al.. (2021). Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nature Biomedical Engineering. 5(2). 144–156. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact